慢性胆囊炎腹腔镜胆囊切除不用抗菌素的临床观察

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:kobe20060121
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的:探讨腹腔镜胆囊切除术围手术期不使用抗菌素的安全性、可行性.方法:选择我院2003年3月-2015年4月腹腔镜胆囊切除患者105例,围手术期不用抗菌素患者34例,术前0.5-2h使用、术后未使用患者18例,术前、术后均使用患者53例.观察围手术期不使用抗生素患者的临床指标和预后情况并统计分析.
其他文献
Objective: Although neoadjuvant chemotherapy (NAC) for advanced lung cancer can improve operability and local disease control, the duration of benefit is limited before resistance develops.
Objective: The central nervous system (CNS) is a frequent site of progression in ALK+ NSCLC patients treated with crizotinib, thus good CNS efficacy is of crucial importance for new ALK inhibitors.
Objective: IGNITE (a large, multinational, diagnostic, non-comparative, interventional study;NCT01788163) assessed EGFR mutation frequency in patients with advanced NSCLC of adenocarcinoma (ADC)/non-A
目的: Bulky local tumor (≥4cm)is a poor prognostic factor for early stage cervical cancer patients.Most of the locally advanced cervical cancer patients need postoperative radiotherapy.
Objective: To perform ameta-analysis on diagnosed brain metastases patients treated with whole-brain radiotherapy (WBRT) and stereotactic radiotherapy (SRT) boost versus WBRT alone, or inpatients trea
Objective: As one of the major cancers with a high mortality rate, lung cancer is still a huge health challenge worldwide.Although platinum-based doublet chemotherapy is the most common therapeutic re
Objective: Currently intensity-modulated radiotherapy (IMRT) is regarded as a promising but unproven therapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Objective: c-Met abnormalities can cause resistance to EGFR TKIs in EGFR mutant NSCLC patients (pts).The highly selective c-Met inhibitor tepotinib (MSC2156119J) had promising activity in a phase Ⅰ tr
目的:探讨幽门螺旋杆菌感染与胃癌的临床特征、病理学特征和分期之间的关系.方法:对我院自2010年1月至2013年12月收治的98例胃癌患者,用ABpH2.5-PAS及HE染色区别肠型和弥漫型胃癌,14C-尿素呼吸试验(14C-UBT)对Hp状态进行评估.
目的:通过检测我科120例mCRC患者在治疗前后血清IL-8,VEGF-A,VEGFR-2,TRAIL的浓度变化,分析上述各细胞因子与mCRC化疗疗效及预后的相关性,期望筛选出能够预测贝伐珠单抗疗效和预后的血清学指标。